Previous 10 | Next 10 |
BTIG has initiated Aclaris Therapeutics ( NASDAQ: ACRS ) with a buy saying that the company's oral MK2 inhibitor, zunsemetinib, in phase 2 for several inflammatory conditions, could be attractive given black box warnings associated with JAK inhibitors. The firm has a $32 p...
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Inv...
WAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually present a co...
Aclaris Therapeutics ( NASDAQ: ACRS ) signed a non-exclusive patent license agreement with Eli Lilly ( LLY ) for baricitinib to treat alopecia areata, a hair loss disorder. Under the agreement, Aclaris granted Lilly non-exclusive rights under certain pate...
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with Eli Lilly and Compa...
Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q2 GAAP EPS of -$0.31 beats by $0.05 . Revenue of $1.53M (-15.9% Y/Y) misses by $0.08M . For further details see: Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.05, revenue of $1.53M misses by $0.0...
WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided...
Aclaris Therapeutics ( NASDAQ: ACRS ) appoints over 25 years of pharmaceutical industry experienced in both large and small companies Douglas Manion, M.D., FRCP ( C ), as President and Chief Operating Officer effective August 1, 2022. Dr. Manion will be ...
A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...
Aclaris Therapeutics (NASDAQ:ACRS) has appointed Gail Cawkwell, MD, PhD, as Chief Medical Officer, effective today. Most recently, she served as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance at Intercept Pharmaceuticals, Inc. Earlier this year, Aclaris falls on t...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...